$ABSI

US analysts on October 16, 2026, showed cautious optimism, with price target reductions outpacing increases. Tech, AI, aerospace, defense, and biotech sectors attracted favorable ratings, while consumer discretionary and financials faced pressure. Abbott Labs (ABT) kept Buy rating with $135 target. Absci (ABSI) raised target to $20. AeroVironment (AVAV) initiated with Buy/Outperform ratings. Applied Materials (AMAT) cut target to $580. Analysts favored resilient companies amid recession risks.

Eli Lilly (LLY) has seen significant growth due to its GLP-1 weight-loss drugs, Mounjaro and Zepbound, with a market cap of $1.1 trillion. Competition is intensifying, with companies like Novo Nordisk (NVO), Viking Therapeutics (VKTX), Amgen (AMGN), and Regeneron (REGN) developing new treatments. GLP-1 drugs are also impacting consumer spending, affecting companies like General Mills (GIS). Absci (ABSI) and Telescope Innovations (TELIF) are leveraging AI to aid drug development.

U.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.

HC Wainwright & Co. maintained a Buy rating on Absci (ABSI) with a $16 price target, suggesting a 57.5% upside from the Oct 9 close. The firm highlighted the potential of ABS-201, Absci's lead product candidate, and positive preliminary data on its effects on stem cells.

Absci Corporation (ABSI) announced plans for a Phase 2 trial of ABS-201, an AI-designed antibody for endometriosis, expected to start in mid-2027. The trial will assess efficacy and safety in 150 patients across 10 countries, focusing on pain reduction. ABS-201 targets the prolactin receptor, offering a non-hormonal approach to treatment.

Vicor Corp (VICR) shares rose 13.5% to $208.73 after granting a license for its patents. Other stocks gaining include Securitize (SECZ) +21%, Generac (GNRC) +19.6%, and Arm (ARM) +6.7%. Generac's rise follows a supply deal with Amazon and a price target increase. Micron (MU) gained 5.6% amid a memory stock rally.

Veradermics (MANE) and Absci (ABSI) shares have surged as investors bet on the hair-loss drug market. Veradermics reported positive trial results for an oral minoxidil tablet, while Absci is developing an AI-designed injectable treatment. Both companies face competition and clinical risks, with no new FDA-approved hair-loss drug since the 1990s.

Absci (ABSI) reported Q2 2026 revenue of $0.3M, down from $0.6M in 2025, with a net loss of $33.2M. R&D expenses rose to $22.6M, driven by ABS-201 clinical progress. Cash increased to $201.1M, supported by a $100M financing round, including $40M from Eli Lilly. The company expects ABS-201 data in late 2026 and 2027, with Phase II endometriosis trials starting in Q4 2026. Management highlighted a 2028 cash runway and platform advancements.

Advanced Micro Devices (AMD) filed its first 13F, revealing a $1.31 billion portfolio with six positions. Top holdings include SpaceX, Absci (ABSI), Sanmina (SANM), Nutanix (NTNX), and Quantum Computing (QUBT). AMD's Q2 revenue surged 50.1% YoY to $11.536 billion, with data center revenue doubling. AMD expects Q3 revenue of $13 billion, citing strong AI demand.

Absci Corp shares fell 16.6% in after-hours after reporting Q2 2026 results. According to the company, revenue was $0.3M versus about $1.01M expected and down from $0.6M a year earlier. The per-share loss was $0.21 versus a $0.19 expected loss, with a $33.2M net loss. CEO cited Phase 1 HEADLINE trial interim data, but investors focused on the financial miss.